Neurology:新发癌症诊断与后续脑血管事件风险!

2018-05-10 xing.T MedSci原创

由此可见,新发癌症诊断与脑血管事件的短期风险显著增加有关。

近日,神经病学领域权威取杂志Neurology上发表了一篇研究文章,研究人员旨在通过在一项前瞻性队列研究来评估癌症和脑血管疾病之间的关联。

研究人员分析了来自于卒中地区和种族差异(REGARDS)研究中45岁以上并且在他们的基线研究访视前365天内有医疗保险覆盖的参与者。有癌症或脑血管病史的参与者被排除在外。时间依赖性暴露是通过医疗保险索赔算法确定的新发恶性癌症诊断。参加者从基线研究访视(2003-2007)到2014年接受前瞻性地随访,结局为神经科医师裁决的脑血管事件,被定义为中风(缺血性或出血性)或TIA的复合结果。Cox回归用于评估新发癌症诊断与随后脑血管事件之间的关联。随访时间在离散时间段内建模,以满足比例风险假设。

在6602名符合REGARDS标准的参与者中,1149人在随访期间被诊断为癌症。与无癌症的参与者相比,新诊断癌症与诊断后前30天内的脑血管事件相关(风险比为6.1,95%可信区间为2.7-13.7)。调整人口统计学、居住地区和血管危险因素后,这种关联仍然存在(风险比为6.6,95%可信区间为2.7-16.0)。癌症诊断和超过30天的脑血管事件之间没有任何关系。研究人员认为静脉血栓栓塞高风险的癌症患者表现出与脑血管事件风险具有最强的相关性。

由此可见,新发癌症诊断与脑血管事件的短期风险显著增加有关。

原始出处:

Babak B. Navi,et al.New diagnosis of cancer and the risk of subsequent cerebrovascular events.neurology.2018. https://doi.org/10.1212/WNL.0000000000005636

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1643534, encodeId=3fcd1643534b0, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Jul 13 05:38:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000417, encodeId=2268200041e2e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Apr 18 17:38:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545022, encodeId=b987154502262, content=<a href='/topic/show?id=49f8e1483fb' target=_blank style='color:#2F92EE;'>#癌症诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71483, encryptionId=49f8e1483fb, topicName=癌症诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4a513680507, createdName=ms9833124466084992, createdTime=Sat May 12 06:38:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313876, encodeId=72aa3138e626, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu May 10 19:11:42 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313856, encodeId=6afe3138566d, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 10 17:00:17 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1643534, encodeId=3fcd1643534b0, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Jul 13 05:38:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000417, encodeId=2268200041e2e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Apr 18 17:38:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545022, encodeId=b987154502262, content=<a href='/topic/show?id=49f8e1483fb' target=_blank style='color:#2F92EE;'>#癌症诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71483, encryptionId=49f8e1483fb, topicName=癌症诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4a513680507, createdName=ms9833124466084992, createdTime=Sat May 12 06:38:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313876, encodeId=72aa3138e626, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu May 10 19:11:42 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313856, encodeId=6afe3138566d, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 10 17:00:17 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
    2019-04-18 heli0118
  3. [GetPortalCommentsPageByObjectIdResponse(id=1643534, encodeId=3fcd1643534b0, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Jul 13 05:38:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000417, encodeId=2268200041e2e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Apr 18 17:38:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545022, encodeId=b987154502262, content=<a href='/topic/show?id=49f8e1483fb' target=_blank style='color:#2F92EE;'>#癌症诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71483, encryptionId=49f8e1483fb, topicName=癌症诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4a513680507, createdName=ms9833124466084992, createdTime=Sat May 12 06:38:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313876, encodeId=72aa3138e626, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu May 10 19:11:42 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313856, encodeId=6afe3138566d, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 10 17:00:17 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1643534, encodeId=3fcd1643534b0, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Jul 13 05:38:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000417, encodeId=2268200041e2e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Apr 18 17:38:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545022, encodeId=b987154502262, content=<a href='/topic/show?id=49f8e1483fb' target=_blank style='color:#2F92EE;'>#癌症诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71483, encryptionId=49f8e1483fb, topicName=癌症诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4a513680507, createdName=ms9833124466084992, createdTime=Sat May 12 06:38:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313876, encodeId=72aa3138e626, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu May 10 19:11:42 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313856, encodeId=6afe3138566d, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 10 17:00:17 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
    2018-05-10 131****1460

    学习了受益匪浅

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1643534, encodeId=3fcd1643534b0, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Jul 13 05:38:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000417, encodeId=2268200041e2e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Apr 18 17:38:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545022, encodeId=b987154502262, content=<a href='/topic/show?id=49f8e1483fb' target=_blank style='color:#2F92EE;'>#癌症诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71483, encryptionId=49f8e1483fb, topicName=癌症诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4a513680507, createdName=ms9833124466084992, createdTime=Sat May 12 06:38:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313876, encodeId=72aa3138e626, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu May 10 19:11:42 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313856, encodeId=6afe3138566d, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 10 17:00:17 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
    2018-05-10 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

相关资讯

默克与Illumina即将开发新一代肿瘤测序技术

癌症的诊断的目的一直以来被定义为给患者提供“个性化”和“精准”的医疗服务。但鉴于企业努力追求一种基于基因组数据就能给予最好的个体治疗方案的无所不包的测试,当下的流行词语似乎更倾向于“全面”。 Illumina和默克的生物药公司-默克雪兰诺已经达成合作开发一项全面的新一代肿瘤测序技术,但该协议的财务细节尚未公开。这个协议与去年8月Illumina与阿斯利康,强生旗下Janssen Biote

JCO:癌症诊断一年后的患者症状负担分析

提升肿瘤患者生活质量需要在整个治疗阶段对症状负担给予关注,患者报告结果对达到最优治疗至关重要。但是目前几乎没有对诊断后早期症状的研究,该阶段不理想的症状控制可能司空见惯。对新确诊的肿瘤患者症状负担短期趋势以及危险因素的分析对于指导支持治疗至关重要。

人工智能突破癌症诊断难题:乳腺癌首先获突破

癌症一直在人类健康史上拖下长长的阴影,迟迟没有暴露自己的软肋。现在,人类似乎借助 AI 技术发现了一些端倪。 据 Engadget 报道,以色列贝斯医疗中心 (BIDMC) 和哈佛医学院 (HMS) 合作开发了一项人工智能项目,旨在训练人工智能快速阅读和识别病理图像中的癌细胞。 以色列贝斯医疗中心研究人员 Andrew Beck 解释,这项技术基于深度学习理论。通过向人工智能输入大量有癌细

JCI:基于DNA甲基化的免疫应答标记可以改善癌症诊断

该研究强调了DNA甲基化的功能,其可以用于评估肿瘤免疫反应,并且使用该方法可以改善乳腺癌和其他癌症的诊断和治疗。